The post-hoc analysis of MTAP IHC revealed the loss of expression in 44% of tumors with a significant association of better clinical outcome compared to MTAP-positive tumors (median change of tumor volume −18% vs. 0%). The gene discussed is MTAP; the disease is neoplasm.